BioSpace News Archive

AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate

Evergreen Theragnostics, Inc., a radiopharmaceutical Contract Development and Manufacturing Organization, announced that it has raised $19M in a Series A financing round.

Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1

QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in Global INVICTUS Phase 3 Study

Reinforces PARP7 as a novel therapeutic target and that inhibition of PARP7 induces both antitumor immunity and cancer cell-intrinsic effects

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor Curcumin shows increased anticancer activity when conjugated to proprietary peptide SORT1+ technology significantly widens therapeutic window of traditional cytotoxic cancer treatments

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a multicenter Phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the company’s investigational SHP2 inhibitor, and pembrolizumab (Keytruda ® ), an anti-PD-1 antibody. The trial, which is being sponsored and conducted

Mainstay Medical Holdings plc announced that the U.S. Food and Drug Administration has approved the Company’s Premarket Approval application for ReActiv8®, its implantable neurostimulation system to treat intractable chronic low back pain.

Arçelik, which owns Beko and Grundig, collaborated with leading Turkish businesses to produce the life-saving ventilators on a not-for-profit basis

G1 Therapeutics, Inc. and Genor Biopharma Co. Inc. announced an exclusive license agreement for the development and commercialization of lerociclib in the Asia-Pacific region.